1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Dysgerminoma: new trials by email Literature Review of Dysgerminoma trials Research Report on Dysgerminoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis - Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor | Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2002-06-01 | 2013-01-17 |
Seminoma (1) · Testicular Neoplasms (1)
Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Germinoma (1) · Gonadal Disorders (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Testicular Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
National Cancer Institute (NCI) (1)
United States (1)
Christopher Ryan (1)
U10CA031946 (1)